Table 6.
Summary of dichotomous outcomes for tadalafil
| Number of | Percent with | ||||||
| Outcome | Dose (mg) | Trials | Patients | Tadalafil | Placebo | Relative benefit or risk (95% CI) | NNT/NNTp/NNH(95% CI) |
| Efficacy | |||||||
| Improved erections | 10 | 2 | 215 | 64 | 23 | 2.8 (1.9 to 4.2) | 2.4 (1.9 to 3.4) |
| 20 | 7 | 1542 | 76 | 24 | 3.1 (2.7 to 3.7) | 1.9 (1.7 to 2.1) | |
| 10/20 | 7 | 1651 | 75 | 24 | 3.1 (2.6 to 3.7) | 1.9 (1.8 to 2.1) | |
| Withdrawal | |||||||
| All-cause | 10/20 | 5 | 1334 | 13 | 19 | 0.7 (0.5 to 0.9) | 15 (8.8 to 46) |
| Lack of efficacy | 10/20 | 6 | 1435 | 3.3 | 7.5 | 0.5 (0.3 to 0.7) | 24 (14 to 69) |
| Adverse event | 10/20 | 7 | 1657 | 3.4 | 1.5 | 2.3 (1.1 to 5.1) | 52 (29 to 260) |
| Adverse events | |||||||
| All cause | 10/20 | 3 | 590 | 47 | 25 | 1.8 (1.4 to 2.3) | 4.6 (3.4 to 7.2) |
| Serious | 10/20 | 7 | 1655 | 1.2 | 1.1 | 1.0 (0.4 to 2.8) | not calculated |
| Headache | 10/20 | 7 | 1810 | 13 | 3.4 | 3.5 (2.2 to 5.4) | 11 (8.5 to 14) |
| Dyspepsia | 10/20 | 6 | 1401 | 10 | 0.2 | 12 (4.3 to 35) | 11 (8.8 to 14) |
| Flushing | 10/20 | 6 | 1530 | 4.8 | 0.2 | 7.2 (2.5 to 20) | 24 (18 to 38) |
| Rhinitis | 10/20 | 2 | 712 | 3.1 | 0.5 | 4.5 (0.8 to 24) | not calculated |
NNT is given in standard font, NNTp in bold, and NNH in bold italic. No NNT/NNTp/NNH was calculated unless there was a statistically significant difference